Treating only terminal cancer patients, the Rand (anti-cancer) vaccine produced objective improvement in 35% of 600 patients while another 30% demonstrated subjective improvement. FDA stopped the vaccine's use in a federal court hearing where neither the cancer patients nor their doctors were allowed to testify.